|
|
|
 |
|
 |
|
|
|
 |
|
|
|
|
The NASTAD Viral Hepatitis Program is focused on increasing the
capacity of state and local HIV/AIDS and hepatitis health department programs
to effectively integrate viral hepatitis prevention and care services into
their existing programs to prevent viral hepatitis transmission and enhance
services to populations at risk.
The program, funded through a cooperative agreement with the Centers for
Disease Control and Prevention (CDC), Division of Viral Hepatitis (DVH), works
closely with state and local health department hepatitis C coordinators, who
are responsible for managing the public health response to viral hepatitis at
the state and local level. Program activities include supporting peer technical
assistance on programmatic and policy issues; facilitating information exchange
between health departments, federal agencies and other partners; and developing
materials and other products to assist health departments in their efforts to
integrate hepatitis prevention and care activities into existing programs.
NASTAD’s Viral Hepatitis Public Policy Project, supported through grants from
Roche Pharmaceuticals and Bayer Diagnostics, is also an important piece of
NASTAD’s Viral Hepatitis Program. The Project is dedicated to increasing the
visibility of viral hepatitis as a critical public health issue and to making
adequate funding for viral hepatitis a national priority. Project activities
include educating Members of Congress about viral hepatitis, supporting
increased funding for viral hepatitis initiatives and working with the
Administration and federal partners to provide leadership on viral hepatitis
issues. NASTAD coordinates the Hepatitis C Appropriations Partnership, which is
a coalition of organizations dedicated to increasing funding for hepatitis C,
and participates on the National Viral Hepatitis Roundtable.
|
|
|